Schedule 13G ownership disclosure

ADC THERAPEUTICS SA

Common Shares, par value CHF 0.08 per share · CUSIP: H0036K147

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • ORBIMED ADVISORS LLC

    Shares: 2,530,638.00 · Class: 2.6%

  • ORBIMED CAPITAL LLC

    Shares: 3,437,813.00 · Class: 3.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000947871-25-000166
Form type
SCHEDULE 13G
Filer
ADC Therapeutics SA
CIK
CIK 1771910
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub